Remdesivir for the Treatment of Covid-19-Final Report
Remdesivir for the Treatment of Covid-19-Final Report
复制标题
DOI：
10.1056/nejmoa2007764
复制
发表时间：
2020-11-05
影响因子：
158.5
通讯作者：
Lane, H. Clifford
中科院分区：
文献类型：
--
作者：
Beigel, John H.;Tomashek, Kay M.;Lane, H. Clifford
背景虽然已经评估了几种治疗药物用于治疗2019冠状病毒病（Covid-19），但尚未发现任何抗病毒药物有效。MethodsWe在因Covid-19住院并有下呼吸道感染证据的成人中进行了一项静脉注射瑞德西韦的双盲，随机，安慰剂对照试验。患者被随机分配接受remdesivir（第1天200 mg负荷剂量，随后每天100 mg，最多9天）或安慰剂治疗10天。主要结果是恢复的时间，无论是出院或住院治疗感染控制purposes.ResultsA共1062例患者进行随机分组（541分配到remdesivir和521安慰剂）。接受Remdesivir治疗的患者中位恢复时间为10天（95%可信区间[CI]，9 - 11），而接受安慰剂治疗的患者中位恢复时间为15天（95% CI，13 - 18）（恢复率比，1.29; 95% CI，1.12 - 1.49; P
BackgroundAlthough several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious.MethodsWe conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only.ResultsA total of 1062 patients underwent randomization (with 541 assigned to remdesivir and 521 to placebo). Those who received remdesivir had a median recovery time of 10 days (95% confidence interval [CI], 9 to 11), as compared with 15 days (95% CI, 13 to 18) among those who received placebo (rate ratio for recovery, 1.29; 95% CI, 1.12 to 1.49; P